30.07

2.59% +0.76

After Hours: 30.07

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is currently priced at $30.07, with a 24-hour trading volume of 327.42K. It has seen a +2.59% increased in the last 24 hours and a -7.42% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $29.57 pivot point. If it approaches the $30.62 resistance level, significant changes may occur.

Previous Close:

$29.31

Open:

$29.46

24h Volume:

327.42K

Market Cap:

$1.65B

Revenue:

$607.52M

Net Income/Loss:

$1.32M

P/E Ratio:

41.19

EPS:

0.73

Net Cash Flow:

$110.53M

1W Performance:

+2.28%

1M Performance:

-7.42%

6M Performance:

+32.35%

1Y Performance:

-18.18%

1D Range:

$29.17

$30.19

52W Range:

$21.99

$38.09

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

301-838-2500

Address

1550 East Gude Drive, Rockville, MD

Employee

422

Twitter

@Supernus_Pharma

Next Earnings Date

2024-05-08

Latest SEC Filings

SUPN's Discussions on Twitter

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

GlobeNewswire Inc.

Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data

Supernus Pharmaceuticals Inc (SUPN) Revenue 2024

SUPN reported a revenue (TTM) of $607.52 million for the quarter ending December 31, 2023, a -8.95% decline year-over-year.

Supernus Pharmaceuticals Inc (SUPN) Net Income 2024

SUPN net income (TTM) was $1.32 million for the quarter ending December 31, 2023, a -97.83% decrease year-over-year.

Supernus Pharmaceuticals Inc (SUPN) Cash Flow 2024

SUPN recorded a free cash flow (TTM) of $110.53 million for the quarter ending December 31, 2023, a -5.05% decrease year-over-year.

Supernus Pharmaceuticals Inc (SUPN) Earnings per Share 2024

SUPN earnings per share (TTM) was -$0.0026 for the quarter ending December 31, 2023, a -100.25% decline year-over-year.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.